- Home
- ONEG vs QNCX Comparison
ONEG vs QNCX Comparison
Compare ONEG & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONEG | QNCX |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | Hong Kong | United States |
| Employees | 26 | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 167.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ONEG | QNCX |
|---|---|---|
| Price | $1.49 | $0.12 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 334.8K | ★ 123.6M |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.13 |
| 52 Week High | $13.50 | $4.55 |
Technical Indicators
Market Signals| Indicator | ONEG | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 33.09 | 27.25 |
| Support Level | N/A | N/A |
| Resistance Level | $2.28 | $0.98 |
| Average True Range (ATR) | 0.77 | 0.10 |
| MACD | -0.24 | 0.09 |
| Stochastic Oscillator | 2.88 | 2.22 |
Price Performance
Historical ComparisonAbout ONEG OneConstruction Group Limited Ordinary Shares
OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project includes performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.